- Investing Ideas
- /
- Chinese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Chinese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
6
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
6 companies
Xiamen Amoytop Biotech
Market Cap: CN¥33.8b
Engages in research, development, production, and sale of recombinant protein drugs in China.
688278
CN¥83.08
7D
-2.6%
1Y
48.8%
Shanghai OPM Biosciences
Market Cap: CN¥6.1b
Provides cell culture media and CDMO services in China and internationally.
688293
CN¥53.70
7D
-3.3%
1Y
101.3%
Dizal (Jiangsu) Pharmaceutical
Market Cap: CN¥35.3b
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases.
688192
CN¥76.74
7D
-7.9%
1Y
103.8%
Zhejiang Jolly PharmaceuticalLTD
Market Cap: CN¥13.2b
Engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally.
300181
CN¥19.06
7D
-4.2%
1Y
40.9%
Nanjing Vazyme Biotech
Market Cap: CN¥9.7b
Offers technology solutions for life science, biomedicine, and in vitro diagnostics.
688105
CN¥24.40
7D
-6.0%
1Y
19.6%
Shanghai Allist Pharmaceuticals
Market Cap: CN¥51.3b
A pharmaceutical company, engages in the research and development of tumor-targeted drugs in China.
688578
CN¥114.00
7D
25.6%
1Y
133.7%